0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-16C13667
Home | Market Reports | Health| Health Conditions
Global Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market Research Report 2023
BUY CHAPTERS

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Research Report 2025

Code: QYRE-Auto-16C13667
Report
September 2025
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

The global market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Alpha-1 Antitrypsin Deficiency Augmentation Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alpha-1 Antitrypsin Deficiency Augmentation Therapy.
The Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alpha-1 Antitrypsin Deficiency Augmentation Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report

Report Metric Details
Report Name Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
CAGR 5%
Segment by Type
  • Glassia
  • Aralast NP
  • Prolastin C
  • Others
Segment by Application
  • Hospitals
  • Specialty Clinics
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Grifols, CSL, Baxter, Kamada, Takeda, Abeona
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Alpha-1 Antitrypsin Deficiency Augmentation Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market report?

Ans: The main players in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona

What are the Application segmentation covered in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market report?

Ans: The Applications covered in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market report are Hospitals, Specialty Clinics

What are the Type segmentation covered in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market report?

Ans: The Types covered in the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market report are Glassia, Aralast NP, Prolastin C, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Glassia
1.2.3 Aralast NP
1.2.4 Prolastin C
1.2.5 Others
1.3 Market by Application
1.3.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2020-2031)
2.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Region
2.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Region (2020-2025)
2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Region (2026-2031)
2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Dynamics
2.3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Trends
2.3.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
2.3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
2.3.4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue
3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2020-2025)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
3.4 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
3.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2024
3.5 Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy Head office and Area Served
3.6 Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, Product and Application
3.7 Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Type
4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2020-2025)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2026-2031)
5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Application
5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Application (2020-2025)
5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
6.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
8.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
9.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
9.4 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2020-2031)
10.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Grifols
11.1.1 Grifols Company Details
11.1.2 Grifols Business Overview
11.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.1.5 Grifols Recent Development
11.2 CSL
11.2.1 CSL Company Details
11.2.2 CSL Business Overview
11.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.2.5 CSL Recent Development
11.3 Baxter
11.3.1 Baxter Company Details
11.3.2 Baxter Business Overview
11.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.3.5 Baxter Recent Development
11.4 Kamada
11.4.1 Kamada Company Details
11.4.2 Kamada Business Overview
11.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.4.5 Kamada Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.5.5 Takeda Recent Development
11.6 Abeona
11.6.1 Abeona Company Details
11.6.2 Abeona Business Overview
11.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
11.6.5 Abeona Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Glassia
 Table 3. Key Players of Aralast NP
 Table 4. Key Players of Prolastin C
 Table 5. Key Players of Others
 Table 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region (2020-2025)
 Table 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region (2026-2031)
 Table 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
 Table 13. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
 Table 14. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
 Table 15. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
 Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2020-2025)
 Table 18. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2024)
 Table 19. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, Headquarters and Area Served
 Table 22. Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, Product and Application
 Table 23. Global Key Players of Alpha-1 Antitrypsin Deficiency Augmentation Therapy, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2020-2025)
 Table 27. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2026-2031)
 Table 29. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2020-2025)
 Table 31. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2026-2031)
 Table 33. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Grifols Company Details
 Table 49. Grifols Business Overview
 Table 50. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 51. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 52. Grifols Recent Development
 Table 53. CSL Company Details
 Table 54. CSL Business Overview
 Table 55. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 56. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 57. CSL Recent Development
 Table 58. Baxter Company Details
 Table 59. Baxter Business Overview
 Table 60. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 61. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 62. Baxter Recent Development
 Table 63. Kamada Company Details
 Table 64. Kamada Business Overview
 Table 65. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 66. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 67. Kamada Recent Development
 Table 68. Takeda Company Details
 Table 69. Takeda Business Overview
 Table 70. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 71. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 72. Takeda Recent Development
 Table 73. Abeona Company Details
 Table 74. Abeona Business Overview
 Table 75. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
 Table 76. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025) & (US$ Million)
 Table 77. Abeona Recent Development
 Table 78. Research Programs/Design for This Report
 Table 79. Key Data Information from Secondary Sources
 Table 80. Key Data Information from Primary Sources
 Table 81. Authors List of This Report


List of Figures
 Figure 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Picture
 Figure 2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2024 VS 2031
 Figure 4. Glassia Features
 Figure 5. Aralast NP Features
 Figure 6. Prolastin C Features
 Figure 7. Others Features
 Figure 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2024 VS 2031
 Figure 10. Hospitals Case Studies
 Figure 11. Specialty Clinics Case Studies
 Figure 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
 Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region: 2024 VS 2031
 Figure 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2024
 Figure 17. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2024
 Figure 19. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2020-2031)
 Figure 21. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2020-2031)
 Figure 25. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region (2020-2031)
 Figure 33. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2020-2031)
 Figure 41. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2020-2031)
 Figure 45. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 49. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 50. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 51. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 52. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 53. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2020-2025)
 Figure 54. Bottom-up and Top-down Approaches for This Report
 Figure 55. Data Triangulation
 Figure 56. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India

SIMILAR REPORTS

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0I20198
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33W11115
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart